(Diphtheria + pertussis (acellular) + tetanus) vaccine is under clinical development by BioNet-Asia and currently in Phase III for Diphtheria. According to GlobalData, Phase III drugs for Diphtheria have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Diphtheria + pertussis (acellular) + tetanus) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Diphtheria + pertussis (acellular) + tetanus) vaccine overview
TdaP vaccine is under development for the prevention of pertusis, tetanus and diphtheria. The vaccine candidate is administered intramuscularly. It constitutes of recombinant acellular pertussis vaccine containing recombinant genetically detoxified pertussis toxin (PTgen), filamentous hemagglutinin (FHA) and pertactin (PRN) in combination with tetanus and diphtheria toxoids.
BioNet-Asia (BioNet) is a unique vaccine expertise offering through its networks access to technology, products and markets. BioNet is headquartered in Bangkok, Thailand.
For a complete picture of (Diphtheria + pertussis (acellular) + tetanus) vaccine’s drug-specific PTSR and LoA scores, buy the report here.